The 2012 US Cancer Diagnostics Market

NEW YORK, April 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The 2012 US Cancer Diagnostics Market

http://www.reportlinker.com/p0365357/The-2012-US-Cancer-Diagnostics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

This report presents a comprehensive analysis of the US cancer diagnostics market, including:

• Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.
• Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
• Ten-year test volume and sales forecasts for 40 cancer diagnostic procedures performed in US hospitals, commercial laboratories, physician offices and cancer clinics.
• Placements and installed base of automated and semiautomated analyzers used for cancer testing.
• Current instrumentation technologies and feature comparison of leading analyzers.
• Sales and market shares of leading suppliers.
• Emerging diagnostic technologies and their potential market applications.
• Product development opportunities.
• Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
• Business opportunities and strategic recommendations for suppliers.

Contains 620 pages and 103 tables

Table of Contents

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. Brest Cancer

2. Lung Cancer

3. Colon and Rectum Cancer

4. Prostate Cancer

5. Stomach Cancer

6. Leukemia

7. Lymphoma

8. Oral Cancer

9. Skin Cancer

10. Uterine Cancer

11. Ovarian Cancer

12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction

2. Tumor Marker Classification

3. ACTH

4. Alpha-Fetoprotein (AFP)

5. Beta-2 Microglobulin

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. Calcitonin

10. Carcinoembrionic Antigen (CEA)

11. Estrogen and Progesterone Receptors

12. Ferritin

13. Gastrin

14. Human Chorionic Gonadotropin (HCG)

15. Insulin

16. NSE

17. Occult Blood

18. PAP Smear/HPV

19. Prostatic Acid Phosphatase (PAP)

20. Prostate-Specific Antigen (PSA)

21. Squamous Cell Carcinoma Antigen (SCC)

22. T and B Lymphocytes

23. TdT

24. Thyroglobulin

25. Tissue Polypeptide Antigen (TPA)

26. Biochemical Tumor Markers

- ADA

- B-Protein

- PNP

- 5'-Nucleotidase

27. Oncogenes

- Abl/abl-bcr

- AIB1

- BCL-2

- BRCA1

- CD44

- C-fos

- C-myb

- C-myc

- CYP-17

- Erb-B

- HPC1

- N-myc

- P40

- P51

- P53

- PIK3CA

- PTI-1

- Ras

- Reg

- Sis

- Src

28. Polypeptide Growth Factors

? Basic Fibroblast Growth Factor

- Beta-TGF

- Cachectin (TNT)

- Calmodulin

- ECFR

- Nerve Growth Factor (NGF)

- Epidermal Growth Factor (EGF)

- Ornithine Decarboxylase

- Transferrin

- Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

- Alpha-Interferon

- B Cell Growth Factors

- B Cell Growth Factor (BCGF)

- Gamma-Interferon

- Interleukin-1 (IL-1)

- Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

- N-Acetylglucosamine

- Actin

- Alpha-Actin

- Antineuronal Antibodies

- 7B2

- B72.3

- Bax

- BCD-F9

- BLCA-4

- Blood Group Antigens A,B,H

- CA 50

- CA 72-4/TAG-72

- CA 195

- CA-242

- CA-549

- CAM 26

- CAR-3

- Cathepsin-D

- Chromogranin A and B

- Cluster 1 Antigen

- Cluster-5/5A Antigen

- CTA

- CU18

- DR-70

- DU-PAN-2

- Endometrial Bleeding Associated Factor

- Endostatin

- Epithelial Membrane Antigen

- Feulgen Hydrolysis

- Fibronectin

- FSH

- (1->3)-L-fucosyltransferase

- Gastrin-Releasing Peptide (GRP)

- GDCFP-15

- Glucagon

- Glycoamines

- H23

- Her-2

- Human Carcinoma Antigen

- HPA

- HSP27

- Intermediate Filaments

- Cytokeratins/CK18/Cyfra 21-1

- Desmin

- Gliofibrillary Acid Protein

- Neurofilaments

- Vimentin

- KA 93

- Kinases

- KP16D3

- LAI

- Leukocyte Common Antigen

- Lewis Antigens

- Lysophosphatidic Acid (LPA)

- Ma 695/Ma 552

- MABDF3

- MAG

- ME1

- Minactivin

- MN/CA9

- MSA

- Mucin Cancer Antigen (MCA)

- Multiple Tumor Suppressor 1

- Myosin

- NEA-130

- NMP22

- OA-519

- Opiod Peptides

- P-glycoprotein

- Pancreatic Oncofetal Antigen (POA)

- Placental Lactogen

- PR92

- Proliferative Index, Ki-67

- Px

- RB Inactivation/Deletion

- Ret

- SCCL 175

- Selectin

- Sialic Acid

- Sialyl SSEA-1/SLX

- SN10

- Somatostatin

- TA-90

- TABA

- Tachykinin

- TAG 12

- TPS

- Troponin

- Tubulin

- VCAM

- VEGF

- Villen

C. Instrumentation Review And

Market Needs

1. Abbott AxSYM

2. Abbott Architect c4000

3. Abbott Architect i2000 Series

4. Abbott Architect ci8200 System

5. Beckman Coulter UniCel Series

6. Beckman Coulter Access

7. Binding Site ESP600

8. bioMerieux Mini Vidas

9. Carolina Chemistries BioLis 24i

10. DiaSorin Liaison

11. Horiba ABX Pentra 400

12. Inverness DS2

13. J&J Vitros ECi/ECiQ

14. J&J Vitros 3600

15. J&J Vitros 5600

16. Olympus AU5400

17. Olympus AU3000i

18. Olympus AU2700

19. Roche Modular Analytics

20. Roche Cobas Integra 400

21. Roche Cobas Integra 400 Plus

22. Roche Elecsys

23. Roche Cobas c311

24. Siemens ADVIA Centaur

25. Siemens Dimension

26. Siemens Dimension RxL Max

27. Siemens Dimension Vista 500

28. Siemens Immulite

29. Siemens Stratus

30. Tosoh AIA-Series

31. Vital Diagnostics ATAC 8000

32. Vital Diagnostics Envoy 500

D. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

- Overview

- ELISA

- Immunofiltration

- Particle-Membrane Capture Immunoassay

- Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

- Chemiluminescence

- Bioluminescence

f. Latex Agglutination

g. Immunoprecipitation

H. Affinity Chromatographu

e. Liposome Flow-Injection Immunoassay

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

- PCR

- DAP-PCR

- Immuno-PCR

- QC-PCR

- CAR

- DNA

- HPA

- LCR

- NASBA

- QBR

- SDA

- 3 SR, and others

4. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. Artificial Intelligence

6. Flow Cytometry

7. Two Dimensional Gel Electrophoresis (2-DGE)

8. Biosensors

9. Competing/Complementing Technologies

a. CT

b. MRI

c. NMR

d. PET

e. Photonics Spectroscopy

E. Personal Testing

U.S.A.

A. Executive Summary

B. Business Environment

1. Health Care Expenditures

2. Cost Consciousness

3. Industry Consolidation

4. Managed Care

5. Hospitals

6. Admissions

7. Length of Stay

8. Industry Diversification

9. Physician Demographics

10. Population Aging

a. Chronic Illness

b. Disease Incidence

c. Susceptibility to Iatrogenesis

d. Multiple Illness Cases

11. Laboratory Regulations

C. Market Structure

1. Centralized Testing

a. Hospitals

b. Commercial/Private Laboratories

2. POT/Decentralized Testing

a. Physician Offices/Group Practices

b. Cancer Clinics

c. Point-Of-Care Testing

d. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers Sales,

Instrument Placements and Market Shares

Major Product Development Opportunities

A. Reagent Kits and Test Systems/Panels

B. Instrumentation

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Profiles

- Abbott

- AdnaGen

- Applied Gene Technologies

- Arca

- Beckman Coulter/Danaher

- Becton Dickinson

- Biomedical Diagnostics

- bioMerieux

- Bio-Rad

- Cepheid

- Correlogic Systems

- Dako

- Decode

- Diadexus

- Diagnocure

- Diasorin

- Eiken Chemical

- Enterix

- Enzo Biochem

- Epigenomics

- Exact Sciences

- Fujirebio

- Gen-Probe

- Guided Therapeutics

- Hologic

- Ipsogen

- Kreatech

- Kyowa Medex

- Life Technologies

- Mackay Life Sciences

- Myriad Genetics

- Nanogen Elitech

- OncoLab

- Otho-Clinical Diagnostics

- Panacea Pharmaceuticals

- Polartechnics

- Polymedco

- PreMD

- Qiagen

- Radient Pharmaceuticals

- Roche

- Scienion

- Sequenom

- Siemens Healthcare

- Takara Bio

- Targeted Diagnostics & Therapeutics

- Tosoh

- Veridex

- Wako Pure Chemicals

- Wallac/PE

- Zila

Appendixes

Appendix I: Major Universities and Research

Centers Developing Cancer Diagnostic

Technology and Applications

Appendix II: Assumed Currency Exchange Rates

List of Tables

Tumor Marker ClassificationMajor Companies Developing or MarketingACTH TestsMajor Companies Developing or MarketingAFP TestsMajor Companies Developing or MarketingBeta-2 Microglobulin TestsMajor Companies Developing or MarketingCA 15-3/27.29 TestsMajor Companies Developing or MarketingCA 19-9 TestsMajor Companies Developing or MarketingCA 125 TestsMajor Companies Developing or MarketingCalcitonin TestsMajor Companies Developing or MarketingCEA TestsMajor Companies Developing or MarketingEstrogen Receptor TestsMajor Companies Developing or MarketingProgesterone Receptor TestsMajor Companies Developing or MarketingFerritin TestsMajor Companies Developing or MarketingGastrin TestsMajor Companies Developing or MarketingHCG TestsMajor Companies Developing or MarketingInsulin TestsMajor Companies Developing or MarketingNSE TestsMajor Companies Developing or MarketingOccult Blood TestsMajor Companies Developing or MarketingPAP Smear/HPV TestsMajor Companies Developing or MarketingPAP TestsMajor Companies Developing or MarketingPSA TestsMajor Companies Developing or MarketingLymphocyte Subclassification TestsBiochemical Markers Potential ApplicationsIn Cancer DiagnosisOncogenes Potential ApplicationsIn Cancer DiagnosisMajor Companies Developing or MarketingOncogene TestsGrowth Factors Potential ApplicationsIn Cancer DiagnosisColony Stimulating Factors PotentialApplications in Cancer DiagnosisLymphokines Potential ApplicationsIn Cancer DiagnosisImmunohistochemical Stains PotentialApplications in Cancer DiagnosisExecutive Summary Table: U.S., Total TumorMarker Test Volume and Sales Forecast byMarket SegmentU.S., Estimated New Cancer Cases and DeathsU.S., Estimated Cancer Death RatesPer 100,000 PopulationU.S., Laboratories Performing TumorMarker Tests by Market SegmentU.S., Hospital Laboratories PerformingTumor Marker Tests by Bed SizeU.S., Commercial/Private LaboratoriesPerforming Tumor Marker Tests byAnnual Test VolumeU.S., Physician Office LaboratoriesPerforming Tumor Marker Tests byPractice SizeU.S., Total Tumor Marker Test VolumeForecast by Market Segment-201U.S., All Market Segments MajorTumor Marker Test Volume ForecastU.S., Hospital Laboratories Major TumorMarker Test Volume Forecast by TestU.S., Commercial/Private LaboratoriesMajor Tumor Marker Test VolumeForecastU.S., Physician Offices/Group PracticesMajor Tumor Marker Test VolumeForecastU.S., Cancer Clinics Major TumorMarker Test Volume Forecast by TestU.S., Total Tumor Marker SalesForecast by Market SegmentU.S., All Market Segment Major TumorMarker Sales Forecast by TestU.S., Hospital Laboratories Major TumorMarker Sales Forecast by TestU.S., Commercial/Private LaboratoriesMajor Tumor Marker Sales Forecast byTestU.S., Physician Offices/Group PracticesMajor Tumor Marker Sales Forecast byTestU.S., Cancer Clinics Major TumorMarker Sales Forecast by TestU.S., ACTH Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., AFP Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Beta-2 Microglobulin Test VolumeAnd Diagnostics Sales Forecast by MarketSegmentU.S., CA 15-3/27.29 Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., CA 19-9 Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., CA-125 Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Calcitonin Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., Cathepsin Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., CEA Test Volume and DiagnosticsSales by Market SegmentU.S., Chromogranin Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., Colon-specific Antigen Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., Cytokeratins Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., Estrogen Receptor Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., Ferritin Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Gastrin Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., HCG Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Insulin Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Interferons Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., Interleukins Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., Lymphocyte Subtyping Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., NSE Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Nucleolar Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Occult Blood Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., Oncogenes Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Pancreatic Oncofetal AntigenTest Volume and DiagnosticsSales Forecast by Market SegmentU.S., PAP Smear Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Parathyroid HormoneTest Volume and DiagnosticsSales Forecast by Market SegmentU.S., Progesterone ReceptorTest Volume and DiagnosticsSales Forecast by Market SegmentU.S., PAP Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., PSA Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., S-100 Protein Test Volume andDiagnostics Sales Forecast by MarketSegmentU.S., Serotonin Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Sialic Acid Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Squamous Cell Carcinoma AntigenTest Volume and DiagnosticsSales Forecast by Market SegmentU.S., TDT Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Thymidine KinaseTest Volume and DiagnosticsSales Forecast by Market SegmentU.S., Thyroglobulin TestVolume and DiagnosticsSales Forecast by Market SegmentU.S., TPA Test Volume and DiagnosticsSales Forecast by Market SegmentU.S., Total Tumor Marker SalesBy Major SupplierU.S., ACTH Testing Market DiagnosticsSales by Major SupplierU.S., AFP Testing Market DiagnosticsSales by Major SupplierU.S., Beta-2 Migroblolulin Testing MarketDiagnostics Sales by Major SupplierU.S., CA 15-3/27.29 Testing MarketDiagnostics Sales by Major SupplierU.S., CA 19-9 Testing Market DiagnosticsSales by Major SupplierU.S., CA 125 Testing Market DiagnosticsSales by Major SupplierU.S., CEA Testing Market DiagnosticsSales by Major SupplierU.S., Ferritin Testing MarketDiagnostics Sales by Major SupplierU.S., HCG Testing MarketDiagnostics Sales by Major SupplierU.S., Insulin Testing MarketDiagnostics Sales by Major SupplierU.S., Parathyroid Hormone TestingMarket Diagnostics Sales by Major SupplierU.S., PAP Testing Market DiagnosticsSales by Major SupplierU.S., Progesterone Receptor Testing MarketDiagnostics Sales by Major SupplierU.S., PSA Testing Market DiagnosticsSales by Major Supplier

To order this report:Diagnostics Industry: The 2012 US Cancer Diagnostics Market

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker